Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has launched the generic equivalent to 5 mg, 30 mg, and 35 mg Actonel (risedronate sodium) tablets, in the US. Teva was first to file, making the product eligible for 180 days of market exclusivity.